Joy Duemke writes and speaks about blood supply resilience, partnerships between blood manufacturers and blood centers, and changes in blood product manufacturing, including platelet production and cell collection for gene therapy.
Joy Duemke is most useful for concise views on blood supply resilience and blood product manufacturing.
Best for
A blood technology or biotech company seeking partnerships and resilience thought leadership.
Not for
Consumer reach, quick product sales, or direct clinical outcome claims.
Key takeaways
Partnerships between manufacturers and blood centers should be built before a crisis, not during one.
Automated whole-blood platelet processing relates to supply, efficiency, and consistency.
Cell collection for gene therapy can be difficult for some genetic hemoglobinopathy patients.
Check first: Confirm audience analytics, job titles, and any sponsorship terms before contacting them.
Main ideas
The blood supply's support system stays invisible until it fails, so partnerships should be built before a crisis · Disruption is something to grow through, and the way forward is one voice aimed at policymakers · Technical bottlenecks in collection and manufacturing are addressed through professional education
Joy Duemke writes and speaks about the blood supply, blood-product manufacturing, and partnerships between manufacturers and blood centers.
In the reviewed LinkedIn posts, they connect industry pressures such as supply-chain disruption and cybersecurity to a practical argument: organizations need to build transparent, coordinated partnerships before a crisis.
The posts also explain technical changes—including cell collection for gene therapy and automated platelet production—by naming the clinical or operational problem and pointing readers to educational programs.
This is a useful account to follow for concise views on blood-sector resilience and manufacturing developments.
Duemke links technical developments and industry coordination to their consequences for patients and the blood supply.
One post explains why collecting enough high-quality cells can be difficult for some patients with genetic hemoglobinopathies, then directs readers to an educational program.
Another frames the shift toward automated whole-blood platelet processing in terms of supply, efficiency, and consistency.
On resilience, the posts argue that manufacturers and blood centers should share visibility and advocacy rather than wait to coordinate during a disruption.
Together, these examples show a practical, education-led approach.
Joy Duemke's material centers on two connected arguments.
Read more
One is about the blood supply as shared infrastructure: manufacturers and blood centers should build partnerships before a crisis tests them, and carry one advocacy message to policymakers and the public.
The other is about technical problems in blood collection and manufacturing — hard-to-collect cells for gene therapy, the shift to automated platelet production — and treats professional education as the practical way to work through them.
The posts are short and mostly tied to panels or courses, so the ideas are stated clearly but not developed at length.
The blood supply's support system stays invisible until it fails, so partnerships should be built before a crisis
Duemke's core argument is about timing.
Read more
The manufacturers, logistics networks, blood centers, and advocacy frameworks that keep blood moving are largely out of sight until a crisis exposes them, so the partnerships that hold the system together have to exist in advance rather than be improvised under pressure. They name three components of that partnership — transparency, mutual investment, and a unified advocacy voice — and frame working together as both good business and what patients depend on.
Describing a panel on organizational resilience, Duemke writes that when conflict, natural disasters, or a pandemic strain the system, "patients can't afford for us to be figuring it out in real time." The post points readers to a longer Substack article, "Building Resilience in Uncertain Times," and closes by asking what is working in readers' own organizations.
The same theme appears later in a more specific form, when Duemke names the pressures rather than speaking generally about disruption.
Disruption is something to grow through, and the way forward is one voice aimed at policymakers
Duemke treats tariff volatility, cybersecurity threats, and supply chain fragmentation as live pressures on the U.S. blood supply — and argues that the response is collective rather than individual.
Read more
When manufacturers and blood centers speak as one to policymakers, to CMS, and to the public, they raise what is at stake and grow the whole ecosystem. They describe true partnership as sharing not just supply chain visibility but the message itself: blood is essential, deserves investment, and saves lives.
From a panel titled "Global Pressures on the U.S. Blood Supply: The New Reality of Internationalized Blood Operations" at the America's Blood Centers Annual Meeting, Duemke writes that "the blood community is small, but our impact is massive," and concludes that carrying the message together means partners "don't just survive disruption, we grow through it."
Technical bottlenecks in collection and manufacturing are addressed through professional education
Two posts follow the same pattern: state the operational or clinical problem plainly, name the patient group or process affected, then direct readers to an accredited education program.
Read more
One concerns collecting enough high-quality hematopoietic progenitor cells for gene therapy, which is difficult for patients with genetic hemoglobinopathies because the underlying disease affects mobilization.
The other concerns platelet manufacturing moving from manual, apheresis-based collection toward automated whole blood processing, with supply, efficiency, and product consistency as the questions that shift raises.
In both, Duemke frames the problem and points readers to training.
The gene-therapy post credits AABB and presenting faculty, including Dr.
John Manis, for a program on optimizing apheresis starting-material collections for sickle cell disease and thalassemia patients, and gives a registration date and link.
The platelet post describes a 30-minute CME-accredited eLearning module from Wiley Health Learning, supported by Terumo Blood and Cell Technologies, and focuses on what the manufacturing shift means rather than how a product performs.
Crediting partners and faculty by name is part of the argument
Across the posts, Duemke attributes the work to the organizations and people who do it — AABB and Dr.
Read more
John Manis for the collection program, Wiley Health Learning and Terumo Blood and Cell Technologies for the platelet module — and keeps the partner's role visible rather than absorbing it into a first-person claim. The posts reflect the partnership argument: the ecosystem advances together.
Rather than presenting the collection topic as their own teaching, the post says "we appreciate AABB and presenting faculty, including Dr. John Manis, behind" the program — separating the sponsorship of the message from the expertise being delivered.
A newcomer will want to know what Duemke argues about the blood supply.
Read more
This post states the argument directly and points to the longer piece where it is developed.
The post argues that the infrastructure carrying blood to patients — manufacturers, logistics networks, blood centers and advocacy frameworks — stays out of sight until a crisis tests it.
Duemke connects that point to a panel on organizational resilience, where manufacturers and blood centers working together through transparency, mutual investment and a unified advocacy voice was described as not only good business but something patients depend on.
The practical warning is about timing: when conflict, natural disasters or a pandemic strain the system, partnerships must already exist rather than be improvised.
The post closes by asking readers what is working in their organizations, turning a conference recap into an invitation to compare notes.
For brands planning a campaign
For a blood technology or biotech company focused on partnership and supply-chain thought leadership, this is close to a ready-made platform: Duemke frames resilience as a shared responsibility between manufacturers and blood centers, not a vendor pitch. A campaign could commission or co-host a follow-up on what a working partnership looks like in practice, rather than ask for a generic brand mention.
It shows the external pressures Duemke sees as live threats to the blood supply and the audience they address in public.
Read more
Speaking on a panel at the America's Blood Centers Annual Meeting, Duemke names three pressures: tariff volatility, cybersecurity threats and supply chain fragmentation.
The argument is for a collective voice: when manufacturers and blood centers speak as one to policymakers, CMS and the public, they raise awareness of what is at stake and strengthen the whole ecosystem.
Duemke calls the blood community small but its impact massive, and describes true partnership as sharing supply chain visibility and a message: blood is essential, deserves investment and saves lives.
The post frames disruption as something to grow through, not only survive.
For brands planning a campaign
This shows an industry-conference and policy-audience presence, not just a publishing habit. A partnership strategy aimed at association audiences could put a company alongside Duemke on a panel or in a co-authored policy-facing statement about tariffs, cybersecurity or fragmentation — topics where a manufacturer's data could strengthen the advocacy message.
It shows Duemke connecting a clinical bottleneck to an education program, turning a technical problem into campaign-shaped content rather than opinion.
Read more
The post opens with a problem: gene therapy is creating new options for patients with genetic hemoglobinopathies, but collecting enough high-quality hematopoietic progenitor cells can be difficult because the underlying disease affects mobilization.
Duemke presents optimizing those collections as a step toward getting more patients with sickle cell and thalassemia to the therapies.
The post credits AABB and presenting faculty, including Dr.
John Manis, for an educational program on the topic and gives a registration date, time and link.
It clearly states the clinical obstacle and calls on readers to attend the program.
For brands planning a campaign
Duemke can bring an education program to an audience when the technical problem is real and clearly stated.
A cell-and-gene company weighing a webinar against a sponsored post can use this as a model: lead with the collection or manufacturing constraint, name the clinical population affected, then introduce the program.
The same structure works for a company's own educational asset.
It is the clearest example of how Duemke explains a manufacturing shift and its implications for supply and consistency.
Read more
The post describes platelet manufacturing moving beyond manual, apheresis-based collection toward more automated whole blood processing.
It highlights a 30-minute CME-accredited eLearning module from Wiley Health Learning, supported by Terumo Blood and Cell Technologies, that explains what the shift means for supply, efficiency and product consistency.
The post focuses on the change and its operational consequences rather than product features or results, and sends readers to enrol for CME credit.
For brands planning a campaign
A manufacturer of blood processing equipment has a clear placement opportunity: fund or co-develop a short accredited education module and let Duemke introduce the industry shift rather than the product. The audience is people who make blood product manufacturing decisions, and the format — a 30-minute course with CME credit — is one a partner can reuse across its own channels.
Joy Duemke argues that manufacturers and blood centers need to work together to prepare for disruptions.
Read more
The posts identify transparency, supply-chain visibility, mutual investment and a shared advocacy message as parts of that work. One names conflict, natural disasters and pandemics as potential tests; another points to tariff volatility, cybersecurity threats and supply-chain fragmentation.
Connects operational risks to their shared consequences for patients, then frames cooperation as a practical response.
For brands planning a campaign
A company seeking stronger industry partnerships could develop a joint thought-leadership series or panel with blood centers. Focus on specific disruption scenarios and show what partners can plan or advocate for together.
A post describes a shift from manual, apheresis-based platelet collection toward more automated whole-blood processing, highlighting supply, efficiency and product consistency as questions for the field.
Read more
It promotes a CME-accredited course supported by Terumo Blood and Cell Technologies. Ask for evidence of the course’s results and the technology’s measured effects before making claims about either.
Introduces a manufacturing change and identifies operational questions for readers to consider.
For brands planning a campaign
A blood-technology or education partner could use this subject for an expert-led explainer or learning resource. Tie claims about benefits to evidence, and distinguish educational content from product promotion.
A post explains that collecting enough high-quality hematopoietic progenitor cells can be challenging for patients with genetic hemoglobinopathies because the disease can affect mobilization.
Read more
It points to an AABB educational program on optimizing apheresis starting-material collections for patients with sickle cell disease and thalassemia.
Sets out a collection challenge, names the patient groups discussed and directs readers to professional education.
For brands planning a campaign
A biotech or blood-technology organization could support technical education connecting collection procedures with gene-therapy manufacturing needs. Ask for clinical evidence before making claims about outcomes.
Joy Duemke's posts show participation in AABB and America's Blood Centers programs, promotion of a Wiley Health Learning CME module supported by Terumo Blood and Cell Technologies, and publication on Substack.
Read more
Ask about any employment, ownership, sponsorship, client, investment or affiliate relationships.
AABB
Mention
Joy Duemke's post thanks AABB and the faculty who presented an educational program on optimizing apheresis collections for stem cell gene therapy.
Read more
It does not state a formal role or commercial relationship with AABB.
Joy Duemke's posts are easiest to explore by theme rather than chronology.
Read more
One cluster argues that blood-supply resilience is built through partnerships between manufacturers, blood centers, logistics networks and advocacy groups before a crisis.
Posts tied to panels name tariff volatility, cybersecurity threats and supply-chain fragmentation as live pressures.
A second cluster covers technical bottlenecks in blood collection and manufacturing — collecting cells for gene therapy in sickle cell disease and thalassemia, and the shift from manual apheresis to automated platelet production — and points readers to accredited education rather than making product claims.
Start with the resilience panel posts for the partnership argument; start with the gene-therapy collection and platelet posts for the technical and educational side.
Blood supply resilienceIndustry partnershipsCell and gene therapy manufacturingBlood collection and apheresisPlatelet manufacturingContinuing medical educationBlood centers
Mooraj treats cell and gene therapy as a manufacturing and delivery problem, not just a science story.
Read more
The posts focus on access — fewer than one in five eligible patients can get treatment — and return to collaboration, manufacturing economics and Europe's competitive position.
Mooraj works at the level of industry working groups and access policy across advanced therapies. Duemke's examples focus on blood collection, platelet production and blood-center partnerships.
Lewis also writes about life-sciences manufacturing and industry combinations.
Read more
One post explains the SimoTech acquisition and argues that complex manufacturing problems are solved by aligning engineering, quality, automation and operations.
Lewis aggregates pharma industry developments and writes from a digital-manufacturing and project-delivery angle. Duemke focuses more on blood supply, blood centers and clinician education.
Metzger's posts are first-person leadership reflections on manufacturing and supply operations.
Read more
The Ferring farewell cites end-to-end supply accountability, safety and quality, and two first-in-class approvals; the Sandoz post marks a high-volume biosimilar plant and links it to access.
Metzger speaks as an executive about company milestones and portfolios. Duemke's material is more external-facing, focusing on panels and education programs in blood.
Placement read: Joy Duemke’s posts point to a small, focused LinkedIn following, not a broad general-business or consumer audience.
Read more
The account snapshot shows 1,866 followers as of 8 October 2026.
The posts target people working in blood banking, transfusion medicine, cell and gene therapy collection, platelet manufacturing, and blood-supply resilience—the same professional space as a campaign to strengthen industry partnerships and thought leadership on supply-chain resilience.
For a blood technology or biotech company pursuing those goals, the audience could help reach blood-center operators, manufacturing and logistics specialists, and policy-facing partners.
Before committing, ask for audience survey results or platform analytics on followers’ job titles, industries, seniority, and geography, plus recent LinkedIn results for comparable topics and formats—especially partnership/resilience posts, technical posts on cell collection or platelet production, and sponsored placements—to compare reach and engagement against the campaign’s aims.
LinkedIn followers
1,866
LinkedIn profile snapshot for the account that published the posts · 2026-10-08
The posts do not document any partnership or sponsorship format that Joy Duemke offers.
Read more
They describe collaboration between blood manufacturers and blood centers and promote third-party educational programs—an AABB webinar on cell collection for gene therapy and a Wiley Health Learning CME module supported by Terumo Blood and Cell Technologies—but do not state that Duemke was paid or engaged as a sponsor.
No rate, deliverable or package is listed.
A brand considering sponsorship should request terms and format details directly.
A blood technology or biotech company looking to strengthen industry partnerships and lead on supply-chain resilience is a strong match for Joy Duemke.
Read more
Their posts make the case that manufacturers and blood centers have to build relationships before a crisis, not during one.
One describes a panel on organizational resilience and argues that transparency, mutual investment, and a unified advocacy voice are what patients depend on.
Another covers a panel at the America's Blood Centers Annual Meeting on global pressures, naming tariff volatility, cybersecurity threats, and supply-chain fragmentation, and calling the blood community small but its impact massive.
That is ready-made thought-leadership territory for a partner: the case is stated, the audiences are named (policymakers, CMS, blood centers), and the call is for shared supply-chain visibility rather than a vendor pitch.
They also have a repeatable education format.
Two posts take a real technical or operational problem, state it plainly, and direct readers to an accredited program — an AABB session on collecting cells for stem cell gene therapy in sickle cell disease and thalassemia, and a 30-minute CME module on the shift from manual apheresis to automated whole-blood platelet production.
For a company with information to contribute on collection, manufacturing, or logistics, that structure offers a practical path: lead with the constraint, name who is affected, bring the company's data, and let them make the industry case.
Before committing, ask for audience analytics and discuss sponsorship terms directly; their LinkedIn profile shows 1,866 followers, and no rate, package, or inquiry route is published in the posts.
When to choose a specialist
A campaign aimed at broad consumer reach, quick product-sales conversion, or direct claims about clinical outcomes is a poor match.
Read more
Joy Duemke's LinkedIn profile shows 1,866 followers, and their posts address people working in blood banking, transfusion medicine, cell and gene therapy collection, platelet manufacturing, and supply policy.
That is not a consumer or general-business audience.
Their writing is also a mismatch for sales-led promotion.
Posts about platelet manufacturing and gene-therapy cell collection focus on the operational change and its consequences — supply, efficiency, product consistency — rather than product features or measured results.
The post on automated platelet production points to an accredited course supported by Terumo Blood and Cell Technologies, but does not provide information about the technology's effects; the cell-collection post points to an AABB education program without making clinical outcome claims.
A campaign requiring the creator to assert product performance, recruit patients, or drive direct purchases would ask for content their posts do not show.
Before proceeding, ask for sponsorship terms and performance data, including engagement rates, click results, registration numbers, and audience composition.
A consumer wellness brand, a general SaaS company, or a biotech seeking direct-to-patient recruitment would be better served by a different creator unless those discussions establish a fit.
A worked campaign example
A blood technology company wants to strengthen industry partnerships and thought leadership on supply-chain resilience. A workable three-month angle is a co-hosted resilience series that turns Duemke's stated argument into a practical agenda rather than a one-off brand mention.
Month one — define the shared problem.
Use two named disruption scenarios Duemke already treats as live: tariff volatility and cybersecurity threats to the blood supply.
The company contributes operational data on where supply-chain visibility breaks down; Duemke frames the consequences for patients and blood centers.
The output is a co-authored LinkedIn piece or short explainer that follows Duemke's established structure: state the constraint, name who is affected, explain why the partnership has to exist before the crisis, and end with a question that invites blood-center operators to compare notes.
Month two — run the educational asset.
Build a 30-minute module in an accredited-style format on one scenario, modelled on the format Duemke uses when introducing platelet manufacturing and gene-therapy cell collection.
The company supplies the technical detail; Duemke introduces the industry shift and the stakes.
Keep claims tied to information that can be substantiated and separate education from product promotion.
Register the module for continuing education credit where the relevant professional body allows it, because that format is used with this audience.
Month three — take the message to the association audience.
Duemke's America's Blood Centers Annual Meeting post shows a conference and policy-facing presence, so the final step is a panel or joint statement aimed at policymakers, CMS, and the public.
The message is the one Duemke already uses: blood is essential, deserves investment, and saves lives.
The company adds the manufacturing and logistics information; Duemke carries the collective-voice argument.
Measure registrations, panel attendance, and downstream requests for the module, and ask Duemke for LinkedIn analytics on job title, industry, and seniority so results can be judged against the right audience.
Two practical cautions: reach is likely modest given the 1,866-follower base, so pair the series with distribution through the partner's own channels and the relevant association; and no sponsorship terms are published in the posts here, so agree scope, deliverables, and payment directly before any work starts.
The full Substack article "Building Resilience in Uncertain Times" and the two referenced education courses are not described in the posts here, so their content cannot be assessed.
Choose Hussain Mooraj when a campaign centers on patient access and commercial delivery for cell and gene therapies, especially in Europe.
Read more
The posts describe a Rome working group where fewer than one in five eligible patients can access therapies, with panels repeatedly returning to access as the frontier.
They also cover a Deloitte NextGen Therapies summit on clinical-to-commercial planning, site readiness, reimbursement, and supply-chain enablement.
For a blood-technology or biotech company seeking to convene payers, providers, manufacturers, and investors around access, Mooraj offers a closer starting point than Duemke's blood-center resilience framing.
Mooraj's posts offer event-recap thought leadership, not practical blood-supply operations.
They do not discuss tariff volatility, cybersecurity, blood-center logistics, or the manufacturer–blood center partnership model Duemke covers.
A buyer switching from Duemke to Mooraj gains access and commercialization reach but loses the blood-supply resilience focus and repeatable education format.
Choose Dan Lewis when a campaign needs a broad pharma-manufacturing audience and a news or integration angle, rather than a blood-supply resilience specialist.
Read more
One post is a pharma industry roundup covering licensing, FDA leadership turnover, restructuring, drug sales, and manufacturing policy.
The other marks the completion of an acquisition combining automation and digital manufacturing with project delivery, CQV, quality, and operational readiness.
For a partner seeking to reach pharma manufacturing and facility-lifecycle buyers with a supply-chain visibility message, Lewis offers a wider industry-news and integration platform.
The connection to blood centers and transfusion medicine is weak.
The roundup covers many topics at headline level, while the acquisition post is a corporate integration announcement.
Neither shows the sustained manufacturer–blood center partnership argument or educational formats in Duemke's posts.
A buyer gains broader pharma-manufacturing context but loses Duemke's specific blood-supply audience and crisis-resilience narrative.
Ask for audience composition and sponsorship terms.
Choose Armin Metzger when a campaign focuses on senior manufacturing and supply leadership at scale, European biologics manufacturing, or biosimilar access.
Read more
The posts cover a decade leading manufacturing and supply operations and R&D at Ferring, including FDA approvals for a microbiome-based therapy and an oncology gene therapy.
They also cover the opening of a high-volume biosimilar manufacturing centre in Lendava, Slovenia, tied to a portfolio ambition and patient access.
For a company seeking an executive voice on facility scale-up, supply reliability, and access through biosimilars, Metzger is a stronger fit than Duemke's blood-supply partnership framing.
Metzger's posts focus on career and facility announcements, not campaign-ready education or blood-center partnerships.
They do not address tariffs, cybersecurity, blood-supply fragmentation, or the specific operational constraints Duemke discusses.
A buyer gains senior manufacturing and biosimilar-access credibility but loses Duemke's direct blood-banking audience and approach to introducing technical education.
Joy Duemke has four LinkedIn posts, plus a LinkedIn profile snapshot dated 8 October 2026.
The posts cover manufacturer–blood center partnership and resilience panels, the shift from manual apheresis to automated whole-blood platelet production, and cell collection for stem cell gene therapy in sickle cell disease and thalassemia.
The four posts do not give publication dates.
The posts describe a Substack article and two education programs, but do not provide their full texts.
No sponsorship terms, rate card, audience demographics or campaign performance results are published in the posts here, and the posts do not mention a signature book, show or earlier body of work.